Northwire Canada EditionWednesday, July 15, 2026
Sign inSubscribe
Northwire
⌕
SGQ 0.400 +5.3% GMX 1.87 −1.6% ALM 0.310 +0.0% WCU 0.010 +0.0% NTH 0.155 −6.1% GGM 0.035 +0.0% FG 0.035 +0.0% EFR 17.76 −4.5% IVN 10.54 −2.3% MASS 0.090 +0.0% LIF 26.61 −2.2% CPAU 0.155 +0.0% PTX 0.105 −4.5% VENT 0.160 +0.0% ANK 0.275 −5.2% ODV 3.34 −0.9% SGQ 0.400 +5.3% GMX 1.87 −1.6% ALM 0.310 +0.0% WCU 0.010 +0.0% NTH 0.155 −6.1% GGM 0.035 +0.0% FG 0.035 +0.0% EFR 17.76 −4.5% IVN 10.54 −2.3% MASS 0.090 +0.0% LIF 26.61 −2.2% CPAU 0.155 +0.0% PTX 0.105 −4.5% VENT 0.160 +0.0% ANK 0.275 −5.2% ODV 3.34 −0.9%

Healthcare

Page 72
  1. Jan 20, 2026 · 16:41 · BLCO

    Bausch + Lomb to release 2025 results Feb. 18

    Bausch + Lomb to release 2025 results Feb. 18

    01
  2. Jan 20, 2026 · 16:39 · ALGO

    Light AI appoints Luna as CEO

    Light AI appoints Luna as CEO

    02
  3. Jan 20, 2026 · 15:40 · THRM

    Therma Bright receives order for 200 Venowave VW5 units

    Therma Bright receives order for 200 Venowave VW5 units

    03
  4. Jan 20, 2026 · 08:03 · BIOV

    BioVaxys Reports Positive Clinical Study Results from Phase 1B/2 PESCO Trial of MVP-S with Pembrolizumab (Keytruda (TM)) and Low-Dose Cyclophosphamide for Patients with Recurrent Epithelial Ovarian Cancer (EOC)

    BioVaxys Reports Positive Clinical Study Results from Phase 1B/2 PESCO Trial of MVP-S with Pembrolizumab (Keytruda (TM)) and Low-Dose Cyclophosphamide for Patients with Recurrent Epithelial Ovarian Cancer (EOC)

    04
  5. Jan 20, 2026 · 07:30 · GLAS

    Glass House Brands Announces Accelerated 2026 Expansion Strategy

    Glass House Brands Announces Accelerated 2026 Expansion Strategy

    05
  6. Jan 20, 2026 · 07:07 · SPLY

    Safe Supply Announces Sale of NIRLAB Drug Analysis Device to Far North Resources Inc., Advancing Indigenous-Led Community Safety and Rapid Drug Identification

    Safe Supply Announces Sale of NIRLAB Drug Analysis Device to Far North Resources Inc., Advancing Indigenous-Led Community Safety and Rapid Drug Identification

    06
  7. Jan 20, 2026 · 07:00 · ALGO

    Light AI Appoints John R. Luna as Chief Executive Officer

    Light AI Appoints John R. Luna as Chief Executive Officer

    07
  8. Jan 20, 2026 · 06:31 · THRM

    Therma Bright Sells an Additional 200-Units of Venowave(TM) to Strategic Distribution Partner Gen-X Med

    Therma Bright Sells an Additional 200-Units of Venowave(TM) to Strategic Distribution Partner Gen-X Med

    08
  9. Jan 20, 2026 · 04:25 · AIDR

    Rocket Doctor AI increases private placement to $5.2M

    Rocket Doctor AI increases private placement to $5.2M

    09
  10. Jan 19, 2026 · 19:22 · TELO

    Telo Genomics arranges $1.2-million debenture financing

    Telo Genomics arranges $1.2-million debenture financing

    10
  11. Jan 19, 2026 · 18:04 · AIDR

    ROCKET DOCTOR AI INC. ANNOUNCES UPSIZE ON LISTED ISSUER FINANCING EXEMPTION (LIFE) NON-BROKERED PRIVATE PLACEMENT

    ROCKET DOCTOR AI INC. ANNOUNCES UPSIZE ON LISTED ISSUER FINANCING EXEMPTION (LIFE) NON-BROKERED PRIVATE PLACEMENT

    11
  12. Jan 19, 2026 · 17:29 · ENBI

    Entheon Announces Execution of Business Combination Agreement with Nutravisor

    Entheon Announces Execution of Business Combination Agreement with Nutravisor

    12
  13. Jan 19, 2026 · 12:36 · BNXT

    Bionxt discusses cladribine ODF study

    Bionxt discusses cladribine ODF study

    13
  14. Jan 19, 2026 · 08:05 · VPT

    Ventripoint Announces Closing of Non-Brokered Units Private Placement

    Ventripoint Announces Closing of Non-Brokered Units Private Placement

    14
← Newer Older →